

CH

---


**Motor Neurone Disease (Sales)  
Limited**

**Annual Report and Financial Statements  
for the Year ended 31 December 2017**

---

Registered no: 01989172

FRIDAY



\*L770S5YA\*

LD6

08/06/2018

#13

COMPANIES HOUSE

# Motor Neurone Disease (Sales) Limited

## Company Information

For the Year ended 31 December 2017

### Directors

Richard Coleman

Neil Fray (*from May 12<sup>th</sup>, 2018*)

David Gray

Tim Kidd (*from September 9<sup>th</sup>, 2017*)

Charlotte Layton (*from September 9<sup>th</sup>, 2017*)

Sally Light

David Oldham (*from September 9<sup>th</sup>, 2017 until May 12<sup>th</sup>, 2018*)

Alun Owen

~~Mike Ranson (*until September 9<sup>th</sup>, 2017*)~~

---

### Company Secretary

Linda Cherrington (*until September 9<sup>th</sup>, 2017*)

### Registered Office

David Niven House

10-15 Notre Dame Mews

Northampton

NN1 2BG

### Auditors

haysmacintyre

10 Queen Street Place

London

EC4R 1AG

### Bankers

Lloyds Bank plc

Public and Community Sector

3<sup>rd</sup> Floor

25 Gresham Street

London

EC2V 7HN

# **Motor Neurone Disease (Sales) Limited**

## **Report of the Directors For the year ended 31 December 2017**

The directors present their report and the audited financial statements for the year ended 31 December 2017.

### **Directors**

The directors who have held office during the period from 1 January 2017 to the date of this report are shown on page 1.

### **Principal activities**

The company engages in sales of merchandise, challenge events and other services to raise funds for the Motor Neurone Disease Association.

### **Review of business and future developments**

The results for the year are set out in the income statement on page 6.

Donations of £19,449 were received on behalf of the Motor Neurone Disease Association. These are included in Amounts owed to parent company but not as income in these accounts. The donations will be paid to the Association within 9 months of the end of the financial year.

This has been another successful year for the company with £69,235 (2016 – 11 months: £135,324) profit being raised to help fund the charitable activities of the Motor Neurone Disease Association via: the online shop, Christmas card sales and Challenge Events. This amount will be paid to the Motor Neurone Disease Association as a gift aid donation.

### **Statement of Directors' responsibilities**

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland". Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the Company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any

time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### **Statement of disclosure of information to Auditors**

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he/she ought to have taken as a director in order to make him/herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

### **Going concern**

As stated in note 1 on page 9, the company is a going concern entity for the foreseeable future.

### **Auditors**

haysmacintyre will be proposed for re-appointment at the forthcoming Board Meeting.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

### **On behalf of the Board:**



Alun Owen

**Director**

12 May 2018

# Motor Neurone Disease (Sales) Limited

## REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF MOTOR NEURONE DISEASE (SALES) LIMITED

---

We have audited the financial statements of Motor Neuron Disease (Sales) Limited (the 'company') for the year ended 31 December 2017 which comprise the Income Statement, the Statement of Financial Position, and the Statement of Changes in Equity, including a summary of significant accounting policies and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2017 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

### Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report has been prepared in accordance with applicable legal requirements.

# Motor Neurone Disease (Sales) Limited

## REPORT OF THE INDEPENDENT AUDITOR'S TO THE MEMBERS OF MOTOR NEURONE DISEASE (SALES) LIMITED

### Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the directors' report and from the requirement to prepare a strategic report.

### Responsibilities of directors


As explained more fully in the directors' responsibilities statement set out on page 2, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our auditor's report.



Kathryn Burton (Senior Statutory Auditor)  
For and on behalf of Haysmacintyre, Statutory Auditors

14th May 2018

10 Queen Street Place  
London  
EC4R 1AG

# Motor Neurone Disease (Sales) Limited

## Income Statement for the year ended 31 December 2017

	Notes	Year ending 31 December 2017 £	11 months ending 31 December 2016 £
Turnover	1	304,717	368,223
Cost of sales		<u>(216,677)</u>	<u>(217,523)</u>
Gross profit		88,040	150,700
Administrative expenses		<u>(18,063)</u>	<u>(14,622)</u>
Operating profit before interest		69,977	136,078
Interest receivable and similar income		404	371
Interest payable and similar charges		<u>(1,146)</u>	<u>(1,125)</u>
Profit on ordinary activities before tax		69,235	135,324
Tax on profit on ordinary activities		<u>-</u>	<u>-</u>
Profit for the financial period		<u>69,235</u>	<u>135,324</u>

All activities are continuing activities.

There is no difference between the result disclosed in the income statement and the result on an unmodified historical cost basis.

There was no other comprehensive income for either financial year.

The notes on pages 9 to 12 form part of these financial statements.


# Motor Neurone Disease (Sales) Limited

## Statement of financial position as at 31 December 2017

	Notes	31 December 2017 £	31 December 2016 £
<b>Current assets</b>			
Stocks	3	30,839	28,318
Debtors and prepayments	4	120,452	165,368
Cash at bank and in hand		93,735	150,420
		<u>245,026</u>	<u>344,106</u>
<b>Creditors: amounts falling due within one year</b>	5	<u>(201,619)</u>	<u>(300,699)</u>
<b>Net assets</b>		<u>43,407</u>	<u>43,407</u>
<b>Capital and reserves</b>			
Called up share capital	6	2	2
Profit and loss account		43,405	43,405
Equity shareholders' funds	7	<u>43,407</u>	<u>43,407</u>

The financial statements have been prepared in accordance with the provisions applicable to Companies subject to the small companies' regime and with FRS102 Section 1A.

The financial statements were approved by the Board of Directors on 12 May 2018 and were signed on its behalf on by:

  
Alun Owen  
Director

The notes on pages 10 to 12 form part of these financial statements.



# Motor Neurone Disease (Sales) Limited

## Statement of changes in equity for the year ended 31 December 2017

	Called up share capital £	Profit and loss account £	Total equity £
Balance at 1 <sup>st</sup> January 2017	2	43,405	43,407
Profit for year	-	69,235	69,235
Gift Aid donation to parent charitable company	-	(69,235)	(69,235)
<b>Balance at 31<sup>st</sup> December 2017</b>	<b>2</b>	<b>43,405</b>	<b>43,407</b>

## Statement of changes in equity for the 11 months ended 31 December 2016

	Called up share capital £	Profit and loss account £	Total equity £
Balance at 1 <sup>st</sup> February 2016	2	43,405	43,407
Profit for the 11 month period	-	135,324	135,324
Gift Aid donation to parent charitable company	-	(135,324)	(135,324)
<b>Balance at 31<sup>st</sup> December 2016</b>	<b>2</b>	<b>43,405</b>	<b>43,407</b>

# Motor Neurone Disease (Sales) Limited

## Notes to the Financial Statements for the year ended 31 December 2017

### 1 Accounting policies

#### Statutory information

The Motor Neurone Disease (Sales) Limited is a private company, limited by shares, domiciled in England and Wales, registration number 01989172. The registered office is David Niven House, 10-15 Notre Dame Mews, Northampton, NN1 2BG.

#### Accounting convention

The financial statements have been prepared in accordance with the historical cost convention and in accordance with FRS 102 Section 1A.

The financial statements are presented in sterling.

#### Going concern

The financial statements have been prepared on the going concern basis. The Company has sufficient working capital and the financial performance for the year is in line with the directors' expectations. The parent undertaking has agreed to provide the necessary support if required to enable the Company to continue with its operations for a period of at least 12 months from the approval of the accounts and so a going concern basis remains appropriate.

#### Turnover

Turnover consists of income derived from the normal operating activities of the company during the year, net of discounts and VAT.

Income comprises event income, sponsorship income and exhibitor fees. Income is also generated from the sale of goods including Christmas cards via the online shop and also through selected outlets across England and Wales.

Income received for events which are taking place after the balance sheet date is carried forward in the balance sheet as deferred income.

#### Expenditure

Expenditure is charged to the income statement in the period in which it relates on an accruals basis. Expenditure which is incurred but relates to a period after the balance sheet date is carried forward in the balance sheet as a prepayment. Stocks are stated at the lower of cost and net realisable value. In general, cost is determined on a first in first out basis and includes transport and handling costs. Net realisable value is the price at which stocks can be sold in the normal course of business after allowing for the costs of realisation. Provision is made where necessary for obsolete, slow moving and defective stocks.

#### Gift Aid

The Company has a policy of paying all its taxable profits to its parent, Motor Neurone Disease Association, under Gift Aid. These Gift Aid payments are now recognised as distributions through equity, rather than as an expense through the profit and loss account. Therefore an operating profit exists at the balance sheet date. This represents a change in accounting policy and the prior period accounts have been restated accordingly. The impact of the restatement was nil on total reserves.

# Motor Neurone Disease (Sales) Limited

## Notes to the Financial Statements for the year ended 31 December 2017

### 1 Accounting policies (continued)

#### Debtors

Short term debtors are measured at their transaction price, less any impairment.

#### Creditors

Short term creditors are measured at the transaction price. Other financial liabilities are measured at fair value.

#### Cash and cash equivalents

Cash and cash equivalents include cash at bank and in hand.

#### Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date, except that a deferred tax asset is only recognised to the extent it is recoverable. Deferred tax is measured using the tax rate that is expected to apply in the periods in which the timing differences are expected to reverse.

### 2 Average number of employees

The average number of employees was nil (2016: nil).

### 3 Stock

	As at 31 December 2017 £	As at 31 December 2016 £
Goods for resale	<u>30,839</u>	<u>28,318</u>

### 4 Debtors: Amounts falling due within one year

	As at 31 December 2017 £	As at 31 December 2016 £
Trade debtors	480	14,998
Other debtors	41,103	56,164
Amounts due from parent company	19,613	8,666
Prepayments	59,256	85,540
	<u>120,452</u>	<u>165,368</u>

# Motor Neurone Disease (Sales) Limited

## Notes to the Financial Statements for the year ended 31 December 2017

### 5 Creditors: amounts falling due within one year

	As at 31 December 2017 £	As at 31 December 2016 £
Trade creditors	29,432	39,790
Loan due to parent company	50,000	50,000
Amounts owed to HMRC	7,905	15,791
Amounts owed to parent company	88,684	167,126
Accruals and other creditors	6,748	6,250
Deferred income	18,850	21,742
	<u>201,619</u>	<u>300,699</u>

### 6 Share Capital

	2017 £	2016 £
Allotted, called up and fully paid share capital:		
2 ordinary shares of £1 each	<u>2</u>	<u>2</u>

### 7 Ultimate parent undertaking

The ultimate parent company is Motor Neurone Disease Association, registered office David Niven House, 10-15 Notre Dame Mews, Northampton, NN1 2BG, which is registered in England and Wales.

### 8 Related parties

MND (Sales) Limited is 100% owned by the Motor Neurone Disease Association. These results are consolidated within the accounts of the parent undertaking. The company has taken advantage of the exemption available under FRS102 Section 33 and not disclosed related party transactions with its parent.